<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="de5fd122-9f44-4685-87ec-77ecefa653c7"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use AMVUTTRA<sup>®</sup> safely and effectively. See full prescribing information for AMVUTTRA. <br/>
      <br/>AMVUTTRA (vutrisiran) injection, for subcutaneous use<br/>
Initial U.S. Approval: 2022
</title>
   <effectiveTime value="20250325"/>
   <setId root="8db0facb-81b6-4006-9239-27dc6409c5d3"/>
   <versionNumber value="7"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="115524410" root="1.3.6.1.4.1.519.1"/>
            <name>Alnylam Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section ID="DLDE">
               <id root="05ef966e-1984-4ff8-9a5c-53ff9507bcc2"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20250325"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71336-1003" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>AMVUTTRA</name>
                        <formCode code="C42946" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="INJECTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>VUTRISIRAN</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator value="25" unit="mg"/>
                              <denominator value="0.5" unit="mL"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="28O0WP6Z1P" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>VUTRISIRAN SODIUM</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="GB4I2JI8UI" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>VUTRISIRAN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="E4GA8884NN" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Phosphoric acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5QWK665956" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="94255I6E2T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, DIHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="0.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43203" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SYRINGE, GLASS"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71336-1003-1" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220613"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA215515" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220613"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="YELLOW" xsi:type="CE">
                              <originalText>clear, colorless-to-yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38299" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUBCUTANEOUS"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="0de09b46-541f-434a-b53a-ff52ecaff212"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="60%" align="left" valign="top"/>
                           <col width="40%" align="right" valign="top"/>
                           <tbody>
                              <tr>
                                 <td>Indication and Usage (<linkHtml href="#S1">1</linkHtml>)</td>
                                 <td>3/2025</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="997dd278-519b-49ce-acb4-b62cec8e0db1"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (<linkHtml href="#S1.1">1.1</linkHtml>)</item>
                           <item>the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits (<linkHtml href="#S1.2">1.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S1.1">
                     <id root="fd89e4f9-de31-46a7-9a10-35f939aa7085"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1  Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis</title>
                     <text>
                        <paragraph>AMVUTTRA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S1.2">
                     <id root="0e987456-dcd4-482e-964f-09c670f02720"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2  Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">AMVUTTRA is indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="8103828e-90c2-4001-9728-5f5f0e3e83e0"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months. (<linkHtml href="#S2.1">2.1</linkHtml>)</item>
                           <item>AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional. (<linkHtml href="#S2.2">2.2</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S2.1">
                     <id root="0453ea01-95c5-4d4c-9b2d-107cfb635475"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Dosage</title>
                     <text>
                        <paragraph>The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months <content styleCode="italics">[see <linkHtml href="#S2.2">Dosage and Administration (2.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="7db8596a-c752-4fbf-bca0-c60d7ba913d1"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Missed Dose</content>
                              </paragraph>
                              <paragraph>If a dose is missed, administer AMVUTTRA as soon as possible. Resume dosing every 3 months from the most recently administered dose.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S2.2">
                     <id root="c0287aa8-dc9d-4584-87b8-1279b860c7d4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2  Administration Instructions</title>
                     <text>
                        <paragraph>AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="aec4fbb5-5afc-4ea5-861d-d2a5523b274c"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Syringe Appearance Before and After Use</content>
                              </paragraph>
                              <table width="90%" styleCode="Noautorules">
                                 <col width="70%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <tbody>
                                    <tr>
                                       <td align="center">
                                          <content styleCode="bold">Before Use</content>
                                          <renderMultiMedia referencedObject="MM1"/>
                                       </td>
                                       <td align="center">
                                          <content styleCode="bold">After Use</content>
                                          <renderMultiMedia referencedObject="MM2"/>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <observationMedia ID="MM1">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-01.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM2">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-02.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="f946ab0b-f40c-4639-9253-f7cad0c5d1a4"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Preparation and Administration</content>
                              </paragraph>
                              <table width="90%" styleCode="Noautorules">
                                 <col width="70%" align="left" valign="top"/>
                                 <col width="30%" align="center" valign="top"/>
                                 <tbody>
                                    <tr>
                                       <td colspan="2">
                                          <list>
                                             <item>
                                                <caption styleCode="italics">1.</caption>
                                                <content styleCode="italics">Prepare the syringe</content>
                                                <br/>If stored cold, allow the syringe to warm to room temperature for 30 minutes prior to use.<br/>Remove the syringe from the packaging by gripping the syringe body.<list>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> touch the plunger rod until ready to inject.</item>
                                                </list>Visually inspect the drug solution for discoloration and particulate matter prior to administration. AMVUTTRA is a sterile, preservative-free, clear, colorless-to-yellow solution. <content styleCode="bold">Do not</content> use if it contains particulate matter or if it is cloudy or discolored.<br/>Check the following:<list listType="unordered" styleCode="Disc">
                                                   <item>Syringe is not damaged, such as cracked or leaking</item>
                                                   <item>Needle cap is attached to the syringe</item>
                                                   <item>Expiration date on syringe label</item>
                                                </list>
                                                <list>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> use the syringe if any issues are found while checking the syringe.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <list>
                                             <item>
                                                <caption styleCode="italics">2.</caption>
                                                <content styleCode="italics">Choose and prepare the injection site</content>
                                                <br/>Choose an injection site from the following areas: the abdomen, thighs, or upper arms.<br/>Avoid the following:<list listType="unordered" styleCode="Disc">
                                                   <item>5-cm area around the navel</item>
                                                   <item>Scar tissue or areas that are reddened, inflamed, or swollen</item>
                                                </list>Clean the chosen injection site.</item>
                                          </list>
                                       </td>
                                       <td valign="bottom">
                                          <renderMultiMedia referencedObject="MM3"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <list>
                                             <item>
                                                <caption styleCode="italics">3.</caption>
                                                <content styleCode="italics">Prepare the syringe for injection</content>
                                                <br/>Hold the syringe body with one hand. Pull the needle cap straight off with other hand and dispose of needle cap immediately. It is normal to see a drop of liquid at the tip of the needle.<list>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> touch the needle or let it touch any surface.</item>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> recap the syringe.</item>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> use the syringe if it is dropped.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </td>
                                       <td valign="middle">
                                          <renderMultiMedia referencedObject="MM4"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <list>
                                             <item>
                                                <caption styleCode="italics">4.</caption>
                                                <content styleCode="italics">Perform the injection</content>
                                                <br/>Pinch the cleaned skin.<br/>Fully insert the needle into the pinched skin at a 45°-90° angle.</item>
                                          </list>
                                       </td>
                                       <td valign="bottom">
                                          <renderMultiMedia referencedObject="MM5"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <list>
                                             <item>
                                                <caption> </caption> Inject all of the medication.<list>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Push the plunger rod as far as it will go</content> to administer the dose and activate the needle shield.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </td>
                                       <td valign="bottom">
                                          <renderMultiMedia referencedObject="MM6"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td>
                                          <list>
                                             <item>
                                                <caption> </caption> Release the plunger rod to allow the needle shield to cover the needle. <list>
                                                   <item>
                                                      <caption> </caption>
                                                      <content styleCode="bold">Do not</content> block plunger rod movement.</item>
                                                </list>
                                             </item>
                                          </list>
                                       </td>
                                       <td valign="bottom">
                                          <renderMultiMedia referencedObject="MM7"/>
                                       </td>
                                    </tr>
                                    <tr>
                                       <td colspan="2">
                                          <list>
                                             <item>
                                                <caption styleCode="italics">5.</caption>
                                                <content styleCode="italics">Dispose of the syringe</content>
                                                <br/>
                                                <content styleCode="bold">        Immediately dispose</content> of the used syringe into a sharps container.</item>
                                          </list>
                                       </td>
                                    </tr>
                                 </tbody>
                              </table>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <observationMedia ID="MM3">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-03.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM4">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-04.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM5">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-05.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM6">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-06.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                           <component>
                              <observationMedia ID="MM7">
                                 <text>Image</text>
                                 <value xsi:type="ED" mediaType="image/jpeg">
                                    <reference value="amvuttra-07.jpg"/>
                                 </value>
                              </observationMedia>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="e790e843-d290-41eb-82c9-c70004656155"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Injection: 25 mg/0.5 mL of vutrisiran as a clear, colorless-to-yellow solution in a single-dose prefilled syringe.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Injection: 25 mg/0.5 mL in a single-dose prefilled syringe. (<linkHtml href="#S3">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="05cd80aa-f87e-46da-bf05-bfbf23507d46"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (<linkHtml href="#S4">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="c71a6373-41d8-4978-b5aa-6e1d6bdbef3f"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Reduced serum vitamin A levels and recommended supplementation: Supplement with the recommended daily allowance of vitamin A. Refer to an ophthalmologist if ocular symptoms suggestive of vitamin A deficiency occur. (<linkHtml href="#S5.1">5.1</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="9d00a323-5912-4410-8771-d4785e015d05"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1  Reduced Serum Vitamin A Levels and Recommended Supplementation</title>
                     <text>
                        <paragraph>AMVUTTRA treatment leads to a decrease in serum vitamin A levels <content styleCode="italics">[see <linkHtml href="#S6.1">Adverse Reactions (6.1)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                        <paragraph>Supplementation at the recommended daily allowance of vitamin A is advised for patients taking AMVUTTRA. Higher doses than the recommended daily allowance of vitamin A should not be given to try to achieve normal serum vitamin A levels during treatment with AMVUTTRA, as serum vitamin A levels do not reflect the total vitamin A in the body.</paragraph>
                        <paragraph>Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness).</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="0d240fdb-d7d8-4e3b-9186-4d2264087c48"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling:</paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Reduced Serum Vitamin A Levels and Recommended Supplementation <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20250325"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (≥5%) were pain in extremity, arthralgia, dyspnea, and vitamin A decreased. (<linkHtml href="#S6.1">6.1</linkHtml>)</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Alnylam Pharmaceuticals at 1-877-256-9526 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S6.1">
                     <id root="997ead7b-8525-45a2-b8ab-5f3c523dc535"/>
                     <code code="90374-0" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>6.1  Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of AMVUTTRA cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>Two Phase 3 randomized, multi-center studies evaluated the safety of AMVUTTRA in 448 transthyretin-mediated amyloidosis (ATTR) patients, including 122 patients with hATTR-PN (HELIOS-A) and 326 patients with ATTR-CM (HELIOS-B) <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. In both studies, patients were instructed to take the recommended daily allowance of vitamin A <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="1f2773b0-dcca-46f6-b29d-0f51701af681"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis</content>
                              </paragraph>
                              <paragraph>In HELIOS-A, 118 patients received at least 18 months of treatment. The mean duration of treatment was 18.8 months (range: 1.7 to 19.4 months). The median patient age at baseline was 60 years and 65% of the patients were male. Seventy percent of AMVUTTRA-treated patients were Caucasian, 17% were Asian, 3% were Black, and 9% were reported as Other. Forty-four percent of patients had the Val30Met mutation in the transthyretin gene; the remaining patients had one of 21 other mutations. At baseline, 70% of patients were in Stage 1 of the disease and 30% were in Stage 2.</paragraph>
                              <paragraph>The most common adverse reactions (at least 5%) were pain in extremity, arthralgia, dyspnea, and vitamin A decreased <content styleCode="italics">(see <linkHtml href="#tab1">Table 1</linkHtml>)</content>.</paragraph>
                              <paragraph>Seventy-four percent of patients treated with AMVUTTRA had normal vitamin A levels at baseline, and 98% of those with a normal baseline developed low vitamin A levels. In some cases, the decreased vitamin A level was reported as an adverse reaction <content styleCode="italics">(see <linkHtml href="#tab1">Table 1</linkHtml>)</content>.</paragraph>
                              <table width="80%" ID="tab1">
                                 <caption>Table 1: Adverse Reactions Reported in at least 5% of Patients Treated with AMVUTTRA in HELIOS-A</caption>
                                 <col width="50%" align="left" valign="top"/>
                                 <col width="50%" align="center" valign="top"/>
                                 <thead>
                                    <tr>
                                       <th styleCode="Lrule Rrule" valign="middle">Adverse Reaction</th>
                                       <th styleCode="Rrule">AMVUTTRA<br/>N=122<br/>%</th>
                                    </tr>
                                 </thead>
                                 <tbody>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Pain in extremity<footnoteRef IDREF="ft1"/>
                                       </td>
                                       <td styleCode="Rrule">15</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Arthralgia<footnote ID="ft1">Comprised of several similar terms</footnote>
                                       </td>
                                       <td styleCode="Rrule">11</td>
                                    </tr>
                                    <tr styleCode="Botrule">
                                       <td styleCode="Lrule Rrule">Dyspnea<footnoteRef IDREF="ft1"/>
                                       </td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                    <tr>
                                       <td styleCode="Lrule Rrule">Vitamin A decreased<footnote>Percentage only reflects those reported as an adverse reaction</footnote>
                                       </td>
                                       <td styleCode="Rrule">7</td>
                                    </tr>
                                 </tbody>
                              </table>
                              <paragraph>In HELIOS-A, two serious adverse reactions of atrioventricular (AV) heart block (1.6%) occurred in patients treated with AMVUTTRA, including one case of complete AV block.</paragraph>
                              <paragraph>Injection site reactions were reported in 5 (4%) patients treated with AMVUTTRA. Reported symptoms included bruising, erythema, pain, pruritus, and warmth. Injection site reactions were mild and transient.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="500d534a-0788-4777-ab91-19f34ba5f137"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis</content>
                              </paragraph>
                              <paragraph>In HELIOS-B, safety was evaluated in 654 patients with ATTR-CM, which included 257 patients treated with AMVUTTRA for ≥30 months, and 77 patients treated with AMVUTTRA for ≥36 months <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>. No new safety issues were identified. Eighty-two percent of patients treated with AMVUTTRA had normal vitamin A levels at baseline, and 80% of those with a normal baseline developed low vitamin A levels.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="6fb666b6-4f01-4878-8103-88a6d080f84f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S8.1">
                     <id root="e3866dca-67b7-40f8-99df-8c419ec345ea"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="5c4a26b4-982c-4fb5-8dcc-a2804ac65695"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There are no available data on AMVUTTRA use in pregnant women to inform a drug-associated risk of adverse developmental outcomes. AMVUTTRA treatment leads to a decrease in serum vitamin A levels, and vitamin A supplementation is advised for patients taking AMVUTTRA. Vitamin A is essential for normal embryofetal development; however, excessive levels of vitamin A are associated with adverse developmental effects. The effects on the fetus of a reduction in maternal serum TTR caused by AMVUTTRA and of vitamin A supplementation are unknown <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                              <paragraph>In animal studies, subcutaneous administration of vutrisiran to pregnant rats resulted in developmental toxicity (reduced fetal body weight and embryofetal mortality) at doses associated with maternal toxicity <content styleCode="italics">(see <linkHtml href="#data">Data</linkHtml>)</content>.</paragraph>
                              <paragraph>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section ID="data">
                           <id root="5e2afb7f-6753-4721-b402-b38c6e320840"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="e212ed07-4989-4386-8830-78eb965ccddd"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="italics">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Subcutaneous administration of vutrisiran (0, 3, 10, or 30 mg/kg/day) to pregnant rats during the period of organogenesis resulted in embryofetal mortality at the high dose and reduced fetal body weight at the mid and high doses, which were associated with maternal toxicity.</paragraph>
                                    <paragraph>Subcutaneous administration of vutrisiran (0, 3, 10, or 30 mg/kg/day) to pregnant rabbits resulted in no adverse effects on embryofetal development.</paragraph>
                                    <paragraph>Subcutaneous administration of vutrisiran (0, 5, 10, or 20 mg/kg) to pregnant rats every 6 days throughout pregnancy and lactation resulted in no adverse developmental effects on the offspring.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="e87c24de-633c-4d1c-9bd0-76351002c6a1"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="facfa1ce-26e5-40dd-ab1d-4a4413f28b7f"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Risk Summary</content>
                              </paragraph>
                              <paragraph>There is no information regarding the presence of vutrisiran in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for AMVUTTRA and any potential adverse effects on the breastfed infant from AMVUTTRA or from the underlying maternal condition.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="d128f36c-4e18-44a3-9950-d9a54151b14d"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in pediatric patients have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="f619de54-4f82-4fac-a6a7-04cc3d1652b9"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No dose adjustment is required in patients ≥65 years of age <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. In HELIOS-A, a total of 46 (38%) patients ≥65 years of age, including 7 (6%) patients ≥75 years of age, received AMVUTTRA In HELIOS-B, a total of 299 (92%) patients ≥65 years old, including 203 (62%) ≥75 years old, received AMVUTTRA. No overall differences in safety or effectiveness were observed between these patients and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="1920b026-bc3b-4cd0-a2ca-5a33bbdb3704"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is recommended in patients with mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] ≥30 to &lt;90 mL/min/1.73 m<sup>2</sup>) <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. AMVUTTRA has not been studied in patients with severe renal impairment or end-stage renal disease.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="47d0b7ca-65f2-4c2a-84e8-fdb7bd88dbe8"/>
                     <code code="88829-7" codeSystem="2.16.840.1.113883.6.1" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>8.7  Hepatic Impairment</title>
                     <text>
                        <paragraph>No dose adjustment is recommended in patients with mild (total bilirubin ≤1 × ULN and AST &gt;1 × ULN, or total bilirubin &gt;1.0 to 1.5 × ULN and any AST) or moderate (total bilirubin &gt;1.5 to 3 × ULN and any AST) hepatic impairment <content styleCode="italics">[see <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]</content>. AMVUTTRA has not been studied in patients with severe hepatic impairment.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="a224408a-50b3-4c75-ae50-e7f0ecfb3008"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>AMVUTTRA contains vutrisiran, a chemically modified double-stranded small interfering ribonucleic acid (siRNA) that targets mutant and wild-type transthyretin (TTR) messenger RNA (mRNA) and is covalently linked to a ligand containing three <content styleCode="italics">N</content>-acetylgalactosamine (GalNAc) residues to enable delivery of the siRNA to hepatocytes.</paragraph>
                  <paragraph>The structural formula of vutrisiran sodium is presented below.</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
                  <paragraph>Dashed lines denote Watson-Crick base pairing</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
                  <paragraph>The molecular formula of vutrisiran sodium is C<sub>530</sub>H<sub>672</sub>F<sub>9</sub>N<sub>171</sub>Na<sub>43</sub>O<sub>323</sub>P<sub>43</sub>S<sub>6</sub> with a molecular weight of 17,290 Da. The molecular formula of the free acid is C<sub>530</sub>H<sub>715</sub>F<sub>9</sub>N<sub>171</sub>O<sub>323</sub>P<sub>43</sub>S<sub>6</sub> with a molecular weight of 16,345 Da.</paragraph>
                  <paragraph>AMVUTTRA is supplied as a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous injection. Each 0.5 mL of solution contains 25 mg of vutrisiran (equivalent to 26.5 mg vutrisiran sodium), 0.2 mg sodium phosphate monobasic dihydrate, 0.7 mg sodium phosphate dibasic dihydrate, 3.2 mg sodium chloride, water for injection, and sodium hydroxide and/or phosphoric acid to adjust the pH to ~7.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amvuttra-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM9">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amvuttra-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="f14daac6-989e-483a-a742-d1385b80ac44"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S12.1">
                     <id root="7251c2a1-ce14-4a5a-bc57-4e24c543bc68"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1  Mechanism of Action</title>
                     <text>
                        <paragraph>Vutrisiran is a double-stranded siRNA-GalNAc conjugate that causes degradation of mutant and wild-type TTR mRNA through RNA interference, which results in a reduction of serum TTR protein and TTR protein deposits in tissues.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="df2ab08a-1297-4daa-b969-1c378c54db7b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The pharmacodynamic effects of AMVUTTRA were evaluated in patients with hATTR-PN and ATTR-CM, treated with 25 mg AMVUTTRA administered by subcutaneous injection once every 3 months.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="5f40fe85-342a-4d1a-914a-f97e211e8add"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis</content>
                              </paragraph>
                              <paragraph>In HELIOS-A <content styleCode="italics">[see <linkHtml href="#S14">Clinical Studies (14)</linkHtml>]</content>, vutrisiran reduced mean serum TTR at steady state by 83%. Similar TTR reductions were observed regardless of Val30Met genotype status, weight, sex, age, or race.</paragraph>
                              <paragraph>Vutrisiran also reduced the mean steady state serum vitamin A by 62% over 9 months <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="13cdb103-8f40-4d64-a1ef-5041328e2e23"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiomyopathy of Wild-type (wt) or Hereditary Transthyretin-mediated Amyloidosis (hATTR)</content>
                              </paragraph>
                              <paragraph>In HELIOS-B, the mean serum TTR reduction profile was similar with that observed in HELIOS-A, and consistent across the subgroups studied (age, sex, race, body weight, anti-drug antibody [ADA] status, ATTR disease type (wtATTR versus hATTR), NYHA class, and baseline tafamidis use).</paragraph>
                              <paragraph>Vutrisiran reduced the mean steady state serum vitamin A by 65% over 36 months. <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                           <component>
                              <section>
                                 <id root="a92993f3-bae9-4972-a772-a6ec273ff75c"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline italics">Cardiac Biomarkers</content>
                                    </paragraph>
                                    <paragraph>Biomarkers associated with heart failure (NT-proBNP and Troponin I) favored AMVUTTRA over placebo.</paragraph>
                                 </text>
                                 <effectiveTime value="20250325"/>
                              </section>
                           </component>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="17085ad0-b9d6-4a66-b829-68c0685c428e"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Cardiac Electrophysiology</content>
                              </paragraph>
                              <paragraph>At a dose 12 times the recommended dosage of 25 mg once every three months, AMVUTTRA does not prolong the QT interval to any clinically relevant extent.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="b84b6b23-c0d0-4c04-8b75-214703e0dab7"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>The pharmacokinetic (PK) properties of AMVUTTRA were evaluated following a single dose in healthy subjects and multiple doses in patients with hATTR amyloidosis, as summarized in Table 2.</paragraph>
                        <table width="100%" ID="Table2">
                           <caption>Table 2: Pharmacokinetic Parameters of Vutrisiran</caption>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="20%" align="left" valign="middle"/>
                           <col width="60%" align="center" valign="middle"/>
                           <thead>
                              <tr>
                                 <th styleCode="Lrule Rrule" colspan="2"/>
                                 <th styleCode="Rrule">Vutrisiran</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="3" align="left">AUC<sub>inf</sub> = area under the concentration-time curve from the time of dosing extrapolated to infinity; AUC<sub>last</sub> = area under the concentration-time curve from the time of dosing to the last measurable concentration; C<sub>max</sub> = maximum plasma concentration; CV = coefficient of variation; RSE = relative standard error; T<sub>max</sub> = time to maximum concentration; Vd/F = apparent volume of distribution</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">General Information</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Dose Proportionality</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">Vutrisiran C<sub>max</sub> showed dose proportional increase while AUC<sub>last</sub> and AUC<sub>inf</sub> were slightly more than dose proportional following single subcutaneous doses ranging from 5 to 300 mg (i.e., 0.2 to 12 times the recommended dose)</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Accumulation</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">No accumulation of vutrisiran was observed in plasma after repeated every 3 months dosage<footnote>After 25 mg every 3 months dosage in hATTR amyloidosis patients</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Absorption</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  T<sub>max</sub> [Median (Range)]</content>
                                 </td>
                                 <td styleCode="Rrule">4 (0.17, 12.0) hours<footnote ID="ft2">After 25 mg single dose in healthy subjects</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Distribution</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Estimated Vd/F (%RSE)</content>
                                 </td>
                                 <td styleCode="Rrule">10.1 (5.8) L<footnote>Based on population PK model estimation</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Protein Binding</content>
                                 </td>
                                 <td styleCode="Rrule">80%<footnote>Vutrisiran plasma protein binding was concentration-dependent and decreased with increasing vutrisiran concentrations (from 78% at 0.5 mcg/mL to 19% at 50 mcg/mL)</footnote>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Organ Distribution</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">Vutrisiran distributes primarily to the liver after subcutaneous dosing</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="3">
                                    <content styleCode="bold">Elimination</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Half-Life [Median (Range)]</content>
                                 </td>
                                 <td styleCode="Rrule">5.2 (2.2, 6.4) hours<footnoteRef IDREF="ft2"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Apparent Clearance [Median (Range)]</content>
                                 </td>
                                 <td styleCode="Rrule">21.4 (19.8, 30) L/hour<footnoteRef IDREF="ft2"/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Metabolism</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Primary Pathway</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">Vutrisiran is metabolized by endo- and exonucleases to short nucleotide fragments of varying sizes within the liver</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td colspan="3" styleCode="Lrule Rrule">
                                    <content styleCode="bold">Excretion</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" colspan="2">
                                    <content styleCode="bold">  Primary Pathway</content>
                                 </td>
                                 <td align="left" styleCode="Rrule">The mean fraction of unchanged vutrisiran eliminated in urine was approximately 19.4% at the recommended dose of 25 mg. The mean renal clearance of vutrisiran ranged from 4.5 to 5.7 L/hour<footnote>After single subcutaneous vutrisiran dose from 5 to 300 mg (i.e., 0.2 to 12 times the recommended dose) in healthy subjects</footnote>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="8d926568-6b6d-4531-9928-088cfa957de7"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Specific Populations</content>
                              </paragraph>
                              <paragraph>No clinically significant differences in the pharmacokinetics of vutrisiran were observed based on age, sex, race, mild and moderate renal impairment (eGFR≥30 to &lt;90 mL/min/1.73 m<sup>2</sup>), or mild (total bilirubin ≤1 × ULN and AST &gt;1 × ULN, or total bilirubin &gt;1.0 to 1.5 × ULN and any AST) and moderate (total bilirubin &gt;1.5 to 3 × ULN and any AST) hepatic impairment. Vutrisiran has not been studied in patients with severe renal impairment, end-stage renal disease, severe hepatic impairment, or in patients with prior liver transplant.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="b423859a-9889-41b4-8c59-80420cebd301"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Drug Interaction Studies</content>
                              </paragraph>
                              <paragraph>No clinical drug-drug interaction studies have been performed with vutrisiran. In vitro studies suggest that vutrisiran is not a substrate or inhibitor of cytochrome P450 enzymes. Vutrisiran is not expected to cause drug-drug interactions by inducing CYP enzymes or modulating the activities of drug transporters.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S12.6">
                     <id root="2cc6721b-932d-49a4-a686-f99f4327b2cd"/>
                     <code code="88830-5" codeSystem="2.16.840.1.113883.6.1" displayName="IMMUNOGENICITY"/>
                     <title>12.6  Immunogenicity</title>
                     <text>
                        <paragraph>The observed incidence of anti-drug antibody (ADA, including neutralizing antibody) is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of ADA in the studies described below with the incidence of ADA in the other studies, including those of AMVUTTRA or of other siRNA products.</paragraph>
                        <paragraph>In HELIOS-A and HELIOS-B studies, 3 (2.5%) and 1 (0.3%) patient treated with AMVUTTRA, respectively, developed transient, low titer anti-drug antibodies. The available data are limited to make definitive conclusions regarding the effect of anti-drug antibodies on pharmacokinetics or pharmacodynamics of AMVUTTRA.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="e5885b06-5b8f-488d-ae8d-88a959bef686"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S13.1">
                     <id root="5891420b-68bc-4373-b576-1a9099c743af"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1  Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20250325"/>
                     <component>
                        <section>
                           <id root="9134511b-064d-45f3-9d8b-e7c7024d15fb"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Carcinogenesis</content>
                              </paragraph>
                              <paragraph>Subcutaneous administration of vutrisiran to male mice (0, 2, 6, or 13 mg/kg once every 4 weeks) for 100 weeks and to female mice (0, 3, 9, or 18 mg/kg once every 4 weeks) for 98 weeks resulted in no increase in tumors.</paragraph>
                              <paragraph>Subcutaneous administration of vutrisiran to male rats (0, 4, 7.5, or 15 mg/kg once every 4 weeks or 15 mg/kg once every 12 weeks) for 99 weeks and to female rats (0, 6, 12.5, or 25 mg/kg once every 4 weeks or 25 mg/kg once every 12 weeks) for 86-87 weeks resulted in no increase in tumors.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="cf111125-fd2e-4f58-be18-1840167ad9c6"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Vutrisiran was negative for mutagenicity in in vitro (bacterial mutagenicity, chromosomal aberration in human blood peripheral lymphocytes) and in vivo (rat bone marrow micronucleus) assays.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                     <component>
                        <section>
                           <id root="d0356871-9651-4ebb-b152-b41029147010"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="underline">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>Subcutaneous administration of vutrisiran (0, 15, 30, or 70 mg/kg/week) to male and female rats prior to and during mating and continuing in females to gestation day 6 resulted in no adverse effects on fertility or reproductive performance.</paragraph>
                           </text>
                           <effectiveTime value="20250325"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S14">
               <id root="2120ded6-78e3-4700-93bc-db9342e9903b"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S14.1">
                     <id root="962c15b8-7a74-49da-b74a-88f15bc44410"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.1 Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis</title>
                     <text>
                        <paragraph>The efficacy of AMVUTTRA was evaluated in a randomized, open-label clinical trial in adult patients with hATTR-PN (HELIOS-A; NCT03759379). Patients were randomized 3:1 to receive 25 mg of AMVUTTRA subcutaneously once every 3 months (N=122), or 0.3 mg/kg patisiran intravenously every 3 weeks (N=42) as a reference group. Ninety-seven percent of AMVUTTRA-treated patients and 93% of patisiran-treated patients completed at least 9 months of the assigned treatment.</paragraph>
                        <paragraph>Efficacy assessments were based on a comparison of the AMVUTTRA arm of HELIOS-A with an external placebo group in another study (NCT01960348) composed of a comparable population of adult patients with polyneuropathy caused by hATTR amyloidosis.</paragraph>
                        <paragraph>The primary efficacy endpoint was the change from baseline to Month 9 in modified Neuropathy Impairment Score +7 (mNIS+7). The mNIS+7 is an objective assessment of neuropathy and comprises the NIS and Modified +7 composite scores. In the version of the mNIS+7 used in the trial, the NIS objectively measures deficits in cranial nerve function, muscle strength, and reflexes, and the +7 assesses postural blood pressure, quantitative sensory testing, and peripheral nerve electrophysiology. The mNIS+7 has a total score range from 0 to 304 points, with higher scores representing a greater severity of disease.</paragraph>
                        <paragraph>The clinical meaningfulness of effects on the mNIS+7 was assessed by the change from baseline to Month 9 in Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) total score. The Norfolk QoL-DN scale is a patient-reported assessment that evaluates the subjective experience of neuropathy in the following domains: physical functioning/large fiber neuropathy, activities of daily living, symptoms, small fiber neuropathy, and autonomic neuropathy. The Norfolk QoL-DN has a total score range from -4 to 136, with higher scores representing greater impairment.</paragraph>
                        <paragraph>Additional endpoints were gait speed, as measured by the 10-meter walk test (10MWT), and modified body mass index (mBMI).</paragraph>
                        <paragraph>Treatment with AMVUTTRA in HELIOS-A resulted in statistically significant improvements in the mNIS+7, Norfolk QoL-DN total score, and 10-meter walk test at Month 9 compared to placebo in the external study (<content styleCode="italics">p</content>&lt;0.001) [Table 3, Figure 1, and Figure 3]. The distributions of changes in mNIS+7 and Norfolk QoL-DN total scores from baseline to Month 9 by percent of patients are shown in Figure 2 and Figure 4, respectively.</paragraph>
                        <paragraph>The change from baseline to Month 9 in modified body mass index nominally favored AMVUTTRA [Table 3].</paragraph>
                        <table width="100%" ID="Table3">
                           <caption>Table 3: Clinical Efficacy Results (Comparison of AMVUTTRA Treatment in HELIOS-A to an External Placebo Control<footnote ID="ft3">External placebo group from another randomized controlled trial (NCT01960348)</footnote>)</caption>
                           <col width="13%" align="left" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <col width="22%" align="center" valign="middle"/>
                           <col width="13%" align="center" valign="middle"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2" align="center">Endpoint<footnote>All endpoints analyzed using the analysis of covariance (ANCOVA) with multiple imputation (MI) method)</footnote>
                                 </th>
                                 <th styleCode="Rrule" colspan="2">Baseline, Mean (SD)</th>
                                 <th styleCode="Rrule" colspan="2">Change from Baseline to Month 9, LS Mean (SEM)</th>
                                 <th styleCode="Rrule" rowspan="2">AMVUTTRA-Placebo<footnoteRef IDREF="ft3"/> Treatment Difference,  LS Mean<br/>(95% CI)</th>
                                 <th styleCode="Rrule" rowspan="2">
                                    <content styleCode="italics">p</content>-value</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule" align="center">AMVUTTRA<br/>N=122<br/>(HELIOS-A)</th>
                                 <th styleCode="Rrule">Placebo<footnoteRef IDREF="ft3"/>
                                    <br/> N=77<br/>(NCT01960348)</th>
                                 <th styleCode="Rrule">AMVUTTRA<br/>(HELIOS-A)</th>
                                 <th styleCode="Rrule">Placebo<footnoteRef IDREF="ft3"/>
                                    <br/>(NCT01960348) 									</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td colspan="7" align="left">CI = confidence interval; LS mean = least squares mean; mBMI = modified body mass index; mNIS = modified Neuropathy Impairment Score; QoL-DN = Quality of Life-Diabetic Neuropathy; SD = standard deviation; SEM = standard error of the mean</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">mNIS+7<footnote ID="ft4">A lower number indicates less impairment/fewer symptoms</footnote>
                                 </td>
                                 <td styleCode="Rrule">60.6 (36.0)</td>
                                 <td styleCode="Rrule">74.6 (37.0)</td>
                                 <td styleCode="Rrule">-2.2 (1.4)</td>
                                 <td styleCode="Rrule">14.8 (2.0)</td>
                                 <td styleCode="Rrule">-17.0 <br/>(-21.8, -12.2)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">p</content>&lt;0.001</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">Norfolk<br/> QoL-DN<footnoteRef IDREF="ft4"/>
                                 </td>
                                 <td styleCode="Rrule">47.1 (26.3)</td>
                                 <td styleCode="Rrule">55.5 (24.3)</td>
                                 <td styleCode="Rrule">-3.3 (1.7)</td>
                                 <td styleCode="Rrule">12.9 (2.2)</td>
                                 <td styleCode="Rrule">-16.2<br/> (-21.7, -10.8)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">p</content>&lt;0.001</td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">10-meter walk test (m/sec)<footnote>A higher number indicates less disability/less impairment</footnote>
                                 </td>
                                 <td styleCode="Rrule">1.01 (0.39)</td>
                                 <td styleCode="Rrule">0.79 (0.32)</td>
                                 <td styleCode="Rrule">0 (0.02)</td>
                                 <td styleCode="Rrule">-0.13 (0.03)</td>
                                 <td styleCode="Rrule">0.13<br/> (0.07, 0.19)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">p</content>&lt;0.001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">mBMI<footnote>mBMI: nominal <content styleCode="italics">p</content>-value; body mass index (BMI; kg/m<sup>2</sup>) multiplied by serum albumin (g/L).</footnote>
                                 </td>
                                 <td styleCode="Rrule">1058 (234)</td>
                                 <td styleCode="Rrule">990 (214)</td>
                                 <td styleCode="Rrule">7.6 (7.9)</td>
                                 <td styleCode="Rrule">-60.2 (10.1)</td>
                                 <td styleCode="Rrule">67.8 <br/>(43.0, 92.6)</td>
                                 <td styleCode="Rrule">
                                    <content styleCode="italics">p</content>&lt;0.001</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="1">A decrease in mNIS+7 indicates improvement<br/>Δ indicates between-group treatment difference, shown as the LS mean difference (95% CI) for AMVUTTRA – placebo</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Figure 1: Change from Baseline in mNIS+7<br/>
(Comparison of AMVUTTRA Treatment in HELIOS-A to an External Placebo Control<footnote>External placebo group from another randomized controlled trial (NCT01960348)</footnote>)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM10"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="1">Categories are mutually exclusive; patients who died before 9 months are summarized in the "Death" category only</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Figure 2: Histogram of mNIS+7 Change from Baseline at Month 9<br/>(Comparison of AMVUTTRA Treatment in HELIOS-A to an External Placebo Control<footnote>External placebo group from another randomized controlled trial (NCT01960348)</footnote>)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM11"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="1">A decrease in Norfolk QoL-DN score indicates improvement<br/>Δ indicates between-group treatment difference, shown as the LS mean difference (95% CI) for AMVUTTRA – placebo</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Figure 3: Change from Baseline in Norfolk QoL-DN Total Score<br/>(Comparison of AMVUTTRA Treatment in HELIOS-A to an External Placebo Control<footnote>External placebo group from another randomized controlled trial (NCT01960348)</footnote>)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM12"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left" valign="top" colspan="1">Categories are mutually exclusive; patients who died before 9 months are summarized in the "Death" category only</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <content styleCode="bold">Figure 4: Histogram of Norfolk QoL-DN Total Score Change from Baseline at Month 9<br/>(Comparison of AMVUTTRA Treatment in HELIOS-A to an External Placebo Control<footnote>External placebo group from another randomized controlled trial (NCT01960348)</footnote>)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM13"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Patients receiving AMVUTTRA in HELIOS-A experienced similar improvements relative to those in the external placebo group in mNIS+7 and Norfolk QoL-DN total score across all subgroups including age, sex, race, region, NIS score, Val30Met genotype status, and disease stage.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <observationMedia ID="MM10">
                           <text>Figure 1</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-10.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM11">
                           <text>Figure 2</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-11.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM12">
                           <text>Figure 3</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-12.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM13">
                           <text>Figure 4</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-13.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="S14.2">
                     <id root="43f1231b-3c5e-4f5c-9380-010f7bb2f48c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>14.2  Cardiomyopathy of Wild-type or Hereditary Transthyretin-mediated Amyloidosis</title>
                     <text>
                        <paragraph>The efficacy of AMVUTTRA was evaluated in a multicenter, international, randomized, double-blind, placebo-controlled trial (HELIOS-B, NCT04153149) in 654 adult patients with wild-type or hereditary ATTR-CM. Patients were randomized 1:1 to receive 25 mg of AMVUTTRA (n=326) subcutaneously once every 3 months, or matching placebo (n=328).</paragraph>
                        <paragraph>Treatment assignment was stratified by baseline tafamidis use (yes versus no), ATTR disease type (wtATTR or hATTR amyloidosis), and by baseline New York Heart Association (NYHA) Class I or II and age &lt;75 years versus all other. At baseline, 40% of patients were on tafamidis. The mean age of study participants was 75 years, 93% were male, 84% were White, 7% were Black or African American, 6% were Asian, 2% did not report race and 1% were race other, 88% had wild-type ATTR, 13% were NYHA Class I, 78% were NYHA Class II, and 9% NYHA Class III. No significant imbalance in baseline characteristics was observed between the two treatment groups.</paragraph>
                        <paragraph>Participants were permitted to initiate open-label tafamidis during the study. A total of 85 participants initiated tafamidis: 44 (22%) in the AMVUTTRA arm and 41 (21%) in the placebo arm. The median time to initiation of tafamidis for these 85 participants was 18 months.</paragraph>
                        <paragraph>The primary efficacy endpoint was the composite outcome of all-cause mortality and recurrent CV events (CV hospitalizations and urgent heart failure [UHF] visits) during the double-blind treatment period of up to 36 months, evaluated in the overall population and in the monotherapy population (defined as patients not receiving tafamidis at study baseline).</paragraph>
                        <paragraph>AMVUTTRA led to significant reduction in the risk of all-cause mortality and recurrent CV events compared to placebo in the overall and monotherapy population of 28% and 33%, respectively (Table 4). The majority of the deaths (77%) were CV-related. A Kaplan-Meier curve illustrating time to first CV event or all-cause mortality is presented in Figure 5.</paragraph>
                        <paragraph>Both components of the primary composite endpoint individually contributed to the treatment effect in the overall and monotherapy population (Table 4).</paragraph>
                        <table width="90%">
                           <caption>Table 4: Primary Composite Endpoint and its Individual Components in HELIOS-B</caption>
                           <col width="25%" align="left" valign="top"/>
                           <col width="25%" align="left" valign="top"/>
                           <col width="12%" align="center" valign="top"/>
                           <col width="13%" align="center" valign="top"/>
                           <col width="12%" align="center" valign="top"/>
                           <col width="13%" align="center" valign="top"/>
                           <thead>
                              <tr styleCode="Botrule">
                                 <th styleCode="Lrule Rrule" rowspan="2" colspan="2" align="center">Endpoint</th>
                                 <th styleCode="Rrule" colspan="2">Overall population</th>
                                 <th styleCode="Rrule" colspan="2">Monotherapy population</th>
                              </tr>
                              <tr>
                                 <th styleCode="Rrule" align="center">AMVUTTRA  <br/>(N=326)</th>
                                 <th styleCode="Rrule" align="center">Placebo  <br/>(N=328)</th>
                                 <th styleCode="Rrule">AMVUTTRA<br/> (N=196)</th>
                                 <th styleCode="Rrule">Placebo  <br/>(N=199)</th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="4">Abbreviations: CI=confidence interval; CV=cardiovascular; UHF=urgent heart failure. <br/>Heart transplantation and left ventricular assist device placement are treated as death. Deaths after study discontinuation are included in the all-cause mortality component analysis.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">Primary composite endpoint</content>
                                    <footnote>Primary composite endpoint defined as: composite outcome of all-cause mortality and recurrent CV events. Primary analysis included at least 33 months (and up to 36 months) follow-up on all patients.</footnote>
                                 </td>
                                 <td styleCode="Rrule">Hazard Ratio (95% CI)<footnote ID="t4ft1">Hazard Ratio (95% CI) and <content styleCode="italics">p</content>-value are based on a modified Andersen-Gill model.</footnote>
                                    <br/>
                                    <content styleCode="italics">p</content>-value<footnoteRef IDREF="t4ft1"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.72 (0.55, 0.93)   <br/>0.01 </td>
                                 <td styleCode="Rrule" colspan="2">0.67 (0.49, 0.93)   <br/>0.02  </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" align="center" colspan="6">
                                    <content styleCode="bold">Components of the Primary Composite Endpoint</content>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">All-cause mortality</content>
                                 </td>
                                 <td styleCode="Rrule">Hazard Ratio (95% CI)<footnote>Hazard Ratio (95% CI) is based on a Cox proportional hazard model.</footnote>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.69 (0.49, 0.98)</td>
                                 <td styleCode="Rrule" colspan="2">0.71 (0.47, 1.06)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule">
                                    <content styleCode="bold">CV hospitalizations and UHF visits</content>
                                 </td>
                                 <td styleCode="Rrule">Hazard Ratio (95% CI)<footnoteRef IDREF="t4ft1"/>
                                 </td>
                                 <td styleCode="Rrule" colspan="2">0.73 (0.55, 0.96)</td>
                                 <td styleCode="Rrule" colspan="2">0.67 (0.47, 0.96)</td>
                              </tr>
                           </tbody>
                        </table>
                        <table width="100%" styleCode="Noautorules">
                           <caption>Figure 5: Time to All-Cause Mortality or First CV Event (Overall population)</caption>
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left">Abbreviations: CI=confidence interval; CV=cardiovascular; HR = hazard ratio.<br/>Heart transplantation and left ventricular assist device placement are treated as death. HR and 95% CI are based on a Cox proportional hazard model.  First CV event = First CV hospitalization or urgent heart failure visit after randomization.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM14"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Results from the subgroup analysis for the primary composite endpoint were consistent across prespecified subgroups in the overall population (Figure 6) and monotherapy population.</paragraph>
                        <table width="100%" styleCode="Noautorules">
                           <caption>Figure 6: Subgroup Analyses of the Primary Composite Endpoint (Overall Population)</caption>
                           <col width="100%" align="center" valign="top"/>
                           <tfoot>
                              <tr>
                                 <td align="left">Abbreviations: ATTR = transthyretin amyloidosis; CI = confidence interval; hATTR = hereditary transthyretin amyloidosis; HR = hazard ratio; NT-pro-BNP = N-terminal prohormone of B-type natriuretic peptide; NYHA = New York Heart Association; wtATTR = wild-type transthyretin amyloidosis.<br/>HR and 95% CI are based on modified Andersen-Gill model analyses.</td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td>
                                    <renderMultiMedia referencedObject="MM15"/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The treatment effect of AMVUTTRA on functional capacity and health status were assessed by the change from baseline to Month 30 in distance walked on 6-Minute Walk Test (6-MWT), and the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score, respectively.</paragraph>
                        <paragraph>At Month 30, the LS mean difference in change from baseline in distance walked on 6-MWT was 22 (95% CI: 8, 35; p=0.002) meters and 25 (95% CI: 7, 44; p=0.006) meters favoring AMVUTTRA over placebo in the overall population and monotherapy population, respectively.</paragraph>
                        <paragraph>At Month 30, the LS mean difference in the change from baseline in KCCQ-OS was 6 (95% CI: 2, 9; p=0.001) and 8 (95% CI: 4, 13; p=0.0003) favoring AMVUTTRA over placebo in the overall population and monotherapy population respectively.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                     <component>
                        <observationMedia ID="MM14">
                           <text>Figure 5</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-14.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                     <component>
                        <observationMedia ID="MM15">
                           <text>Figure 6</text>
                           <value xsi:type="ED" mediaType="image/jpeg">
                              <reference value="amvuttra-15.jpg"/>
                           </value>
                        </observationMedia>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="c5391e42-40a4-4c94-a125-273178bcd2cd"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section ID="S16.1">
                     <id root="b04be663-a763-40e2-842f-f7edc10a0989"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>16.1  How Supplied</title>
                     <text>
                        <paragraph>AMVUTTRA is a sterile, preservative-free, clear, colorless-to-yellow solution for subcutaneous injection. AMVUTTRA is supplied as 25 mg/0.5 mL solution in a single-dose 1-mL prefilled syringe made from Type I glass with stainless steel 29-gauge needle with a needle shield. The prefilled syringe components are not made with natural rubber latex.</paragraph>
                        <paragraph>AMVUTTRA is available in cartons containing one single-dose prefilled syringe each.</paragraph>
                        <paragraph>The NDC is: 71336-1003-1.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section ID="S16.2">
                     <id root="0d6a6c8a-50e6-4249-9af8-e5a9a46e4423"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <title>16.2  Storage and Handling</title>
                     <text>
                        <paragraph>Store at 2°C to 30°C (36°F to 86°F) in the original carton, until ready for use. Do not freeze.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="b3172a55-2320-401d-9ba8-d88436fd9014"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <effectiveTime value="20250325"/>
               <component>
                  <section>
                     <id root="f342705e-e757-4732-86dc-3ef068ec6e04"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Recommended Vitamin A Supplementation</content>
                        </paragraph>
                        <paragraph>Inform patients that AMVUTTRA treatment leads to a decrease in serum vitamin A levels. Instruct patients to take the recommended daily allowance of vitamin A. Advise patients to contact their healthcare provider if they experience ocular symptoms suggestive of vitamin A deficiency (e.g., night blindness) and refer them to an ophthalmologist if they develop these symptoms <content styleCode="italics">[see <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="9a344060-d5d7-4c4e-9deb-5485f742c250"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy</content>
                        </paragraph>
                        <paragraph>Instruct patients that if they are pregnant or plan to become pregnant while taking AMVUTTRA they should inform their healthcare provider. Inform patients of the potential risk to the fetus, including that AMVUTTRA treatment leads to a decrease in serum vitamin A levels <content styleCode="italics">[see <linkHtml href="#S8.1">Use in Specific Populations (8.1)</linkHtml> and <linkHtml href="#S12.2">Clinical Pharmacology (12.2)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20250325"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="80d85856-c057-4f9b-adc9-a6507ab26f91"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>Manufactured for: Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142<br/>AMVUTTRA is a registered trademark of Alnylam Pharmaceuticals, Inc.</paragraph>
               </text>
               <effectiveTime value="20250325"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e866b9a9-03e7-4473-9989-c800a4ee1b04"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 25 mg/0.5 mL Syringe Carton</title>
               <text>
                  <paragraph>NDC 71336-1003-1</paragraph>
                  <paragraph>amvuttra ™<br/>(vutrisiran) injection</paragraph>
                  <paragraph>25 mg/0.5 mL</paragraph>
                  <paragraph>For Subcutaneous Injection by<br/>Healthcare Professional Only</paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Do not use if<br/>seal is broken</paragraph>
                  <paragraph>1 x 25 mg single-dose<br/>prefilled syringe</paragraph>
                  <renderMultiMedia referencedObject="MM16"/>
               </text>
               <effectiveTime value="20250325"/>
               <component>
                  <observationMedia ID="MM16">
                     <text>PRINCIPAL DISPLAY PANEL - 25 mg/0.5 mL Syringe Carton</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="amvuttra-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>